Evaluation of the safety and efficiency of cytotoxic T cell therapy sensitized by tumor antigens original from T‐ALL‐iPSC in vivo

Abstract

AbstractBackgroundSince RNA sequencing has shown that induced pluripotent stem cells (iPSCs) share a common antigen profile with tumor cells, cancer vaccines that focus on iPSCs have made promising progress in recent years. Previously, we showed that iPSCs derived from leukemic cells of patients with primary T cell acute lymphoblastic leukemia (T‐ALL) have a gene expression profile similar to that of T‐ALL cell lines.MethodsMice with T‐ALL were treated with dendritic and T (DC‐T) cells loaded with intact and complete antigens from T‐ALL‐derived iPSCs (T‐ALL‐iPSCs). We evaluated the safety and antitumor efficiency of autologous tumor‐derived iPSC antigens by flow cytometry, cytokine release assay, acute toxicity experiments, long‐term toxicity experiments, and other methods.ResultsOur results indicate that complete tumor antigens from T‐ALL‐iPSCs could inhibit the growth of inoculated tumors in immunocompromised mice without causing acute and long‐term toxicity.ConclusionT‐ALL‐iPSC‐based treatment is safe and can be used as a potential strategy for leukemia immunotherapy.